Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows
Further R&D Shift Towards China
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.
